BWAY vs ABT

For growth investors, BrainsWay Ltd.

(BWAY) is the stronger pick with 28. 3% revenue growth year-over-year, versus 4. 6% for Abbott Laboratories (ABT). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate BrainsWay Ltd. (BWAY) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

4x versus BrainsWay Ltd. at 45. 6x. On forward P/E, Abbott Laboratories is actually cheaper at 15. 9x.

Over the past 5 years, BrainsWay Ltd.

(BWAY) delivered a total return of +291. 0%, compared to -17. 5% for Abbott Laboratories (ABT). Over 10 years, the gap is even starker: BWAY returned +195. 9% versus ABT's +170. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus BrainsWay Ltd. 's 1. 58β — meaning BWAY is approximately 536% more volatile than ABT relative to the S&P 500. On balance sheet safety, BrainsWay Ltd. (BWAY) carries a lower debt/equity ratio of 9% versus 32% for Abbott Laboratories — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BrainsWay Ltd.

(BWAY) is pulling ahead at 28. 3% versus 4. 6% for Abbott Laboratories (ABT). On earnings-per-share growth, the picture is similar: BrainsWay Ltd. grew EPS 300. 0% year-over-year, compared to 133. 6% for Abbott Laboratories. Over a 3-year CAGR, BWAY leads at 24. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus 14. 6% for BrainsWay Ltd. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus 8. 3% for BWAY. At the gross margin level — before operating expenses — BWAY leads at 75. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Abbott Laboratories (ABT) trades at 15.

9x forward P/E versus 84. 2x for BrainsWay Ltd. — 68. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABT: 47. 6% to $128. 71.

In this comparison, ABT (2.

5% yield) pays a dividend. BWAY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +170. 5% 10Y return). BrainsWay Ltd. (BWAY) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +170. 5%, BWAY: +195. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BWAY is a small-cap high-growth stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while BWAY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.